Menopausal hormone therapy and breast cancer incidence

New research suggest that all types of MHT, except topical vaginal estrogens, are associated with increased risks of breast cancer, and that the risks are greater for users of estrogen-progestagen hormone therapy than for estrogen-only hormone therapy. For estrogen-progestagen therapy, the risks were greater if the progestagen was included daily rather than intermittently (eg, for 10-14 days per month).